Brookings Roundtable on Active Medical Product Surveillance: Overivew of Additional Sentinel Activities
The third and concluding webinar of the Sentinel Initiative 101 Series provided overviews of the Federal Partners Collaboration, the Observational Medical Outcomes Partnership (OMOP), and the Brookings Institution’s convening activities.
The webinar featured presentations from Melissa Robb, Project Director for the Sentinel Initiative, Office of Medical Policy, Center for Drug Evaluation and Research, U.S. Food and Drug Administration; Paul Stang, Senior Director of Epidemiology, Johnson & Johnson, and Principal Investigator at OMOP; and Josh Benner, Fellow in Economic Studies and Managing Director, Engelberg Center for Health Care Reform at Brookings. Presentations provided an overview of each activity and defined each activity’s role within the broader Sentinel Initiative.
The final webinar of the series provided additional detail about FDA’s other activities informing the Sentinel Initiative. Members of FDA’s Core Team spoke about the Federal Partners Collaboration; Paul Stang, from Johnson & Johnson and the Observational Medical Outcomes Partnership (OMOP), gave an update on OMOP’s accomplishments and future plans; and Joshua Benner, from the Engelberg Center for Healthcare Reform at Brookings, provided an overview of Brookings Convening Activities.